118373-61-8Relevant articles and documents
ANTI-HEPATITIS B VIRUS AGENT
-
, (2020/10/09)
PROBLEM TO BE SOLVED: To provide an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-associated diseases, containing a nucleic acid analog as an active ingredient. SOLUTION: The anti-hepatitis B virus agent and pr
Syntheses of 2′-deoxy-2′-fluoro-β-d-arabinofuranosyl purine nucleosides via selective glycosylation reactions of potassium salts of purine derivatives with the glycosyl bromide
Sivets, Grigorii G.
supporting information, p. 268 - 271 (2016/01/12)
Syntheses of 9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)-guanine (1) and -adenine (2) were accomplished from readily available 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-α-d-arabinofuranose (3). A new and efficient approach for the synthesis of 1-α-bromide was developed using the mild bromination of α-1-O-benzoate (3). Selective coupling reactions of the bromosugar with purine potassium salts followed by derivatization/and or deprotection of the intermediate blocked 2′-fluoro β-arabinonucleosides resulted in formation of the target compounds with high overall yields.
Isolation, synthesis, and characterization of impurities and degradants from the clofarabine process
Anderson, Bruce G.,Bauta, William E.,Cantrell Jr., William R.,Engles, Tracy,Lovett, Dennis P.
, p. 1229 - 1237 (2013/01/03)
The identification of clofarabine process impurities and their subsequent isolation, synthesis, and characterization is described. Two isomeric process impurities resulting from N6-attachment of a fluoroarabinose to clofarabine were found. Clofarabine's base degradation products, which were different from the process impurities, were also synthesized and characterized. These compounds resulted from modifications to the sugar moiety, the purine ring, or both. A mechanistic rationale for the formation of the various process impurities and degradation products is provided.
